Lexicon Pharmaceuticals (LXRX) Other Non-Current Assets (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has reported Other Non-Current Assets for 17 consecutive years, with $29.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non-Current Assets rose 7780.43% year-over-year to $29.0 million; the TTM figure through Mar 2026 stood at $29.0 million (up 7780.43% YoY), while the FY2025 annual figure was $368000.0, changed 0.0% from the prior year.
• Other Non-Current Assets climbed to $29.0 million in Q1 2026 per LXRX's latest filing, from $368000.0 in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $29.0 million in Q3 2025 and bottomed at $368000.0 in Q4 2024.
• Historically, Other Non-Current Assets has averaged $5.2 million across 5 years, with a median of $828000.0 in 2023.
• Annual changes were most pronounced in 2023 — Other Non-Current Assets sank 89.6% — and 2026, when it jumped 7780.43%.
• Lexicon Pharmaceuticals' Other Non-Current Assets stood at $412000.0 in 2022, then surged by 100.97% to $828000.0 in 2023, then slumped by 55.56% to $368000.0 in 2024, then changed by 0.0% to $368000.0 in 2025, then surged by 7780.43% to $29.0 million in 2026.
• Business Quant data shows LXRX's Other Non-Current Assets at $29.0 million in Q1 2026, $368000.0 in Q4 2025, and $29.0 million in Q3 2025.